RxDoctor Payments Data

Rajeev Srivastava, MD

Cardiology · Jamaica, NYNPI 1598706368

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Boehringer Ingelheim at 46.3% of the total.

$946in general payments, 2019–2025

Across 19 payments — averaging $49.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$438
  • Boston Scientific$173
  • Idorsia Pharmaceuticals US Inc$122
  • Amgen$115
  • AbbVie$39
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$36
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$946100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$946 in reported general payments places this provider in the 55th percentile of 112 cardiology providers in New York.

See all cardiology providers in New York

Medicare billing

Part B allowed, 2024
$762,092
Medicare patients
499
Services billed
4,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$52,131
JanuviaSitagliptin Phosphate17$18,108
JanumetSitagliptin Phos/Metformin Hcl11$16,452
Nebivolol Hcl16$1,628
Valsartan20$712
Metoprolol Succinate73$699
Atorvastatin Calcium89$640
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril15$500
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$473
Omeprazole33$447
Levothyroxine Sodium46$431
Pantoprazole Sodium16$409
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide21$368
Metformin Hcl43$339
Amlodipine Besylate93$337

Paid to pharmacies, not to this prescriber.

Other cardiology in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →